首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Cytokeratin 7 as a Predictive Factor for Response to Concommitant Radiochemotherapy for Locally Advanced Cervical Cancer: A Preliminary Study
【24h】

Cytokeratin 7 as a Predictive Factor for Response to Concommitant Radiochemotherapy for Locally Advanced Cervical Cancer: A Preliminary Study

机译:细胞角蛋白7作为局部晚期宫颈癌同时放化疗反应的预测因素:初步研究

获取原文
获取原文并翻译 | 示例
       

摘要

Background: The role of completion surgery after concurrent radiochemotherapy (CCRC) for advanced cervical cancer remains controversial. Individual predictive factors of CCRC response and survival are mandatory for treatment adaptation and to determine a population who would take interest in completion surgery after CCRC. The aim of this study was to evaluate the ability of biomarkers to predict the response to CCRC. Patients and Methods: Between 1996 and 2008, in 58 patients with advanced cervical cancer for whom pre-therapeutic cone biopsy was available, we tested several biomarkers (ALDH1, CD44, CD24, IDO, Ki67, P63, CK7, p-Stat3, Foxp3 and IDO). Results: Residual disease was found in 49.1% of cases (n=26). We found a significant association between progression-free survival and residual disease on completion hysterectomy (p=0.044). Univariate analysis of the different factors showed that negativity for cytokeratin 7 expression was a strong predictor for the presence of residual tumor (p=0.001). Conclusion: These results are encouraging and CK7 could be used as a predictive factor of response to CCRC.
机译:背景:对于晚期宫颈癌,同时放化疗后完成手术的作用仍存在争议。 CCRC反应和生存的个体预测因素对于治疗适应性和确定对CCRC后完成手术感兴趣的人群是必不可少的。这项研究的目的是评估生物标志物预测对CCRC反应的能力。患者和方法:在1996年至2008年之间,对58例接受治疗前锥切活检的晚期宫颈癌患者,我们测试了几种生物标志物(ALDH1,CD44,CD24,IDO,Ki67,P63,CK7,p-Stat3,Foxp3和IDO)。结果:49.1%的病例中发现残留疾病(n = 26)。我们发现无进展生存期与完成子宫切除术后的残留疾病之间存在显着关联(p = 0.044)。对不同因素的单因素分析表明,细胞角蛋白7表达的阴性是预测是否存在残留肿瘤的重要指标(p = 0.001)。结论:这些结果令人鼓舞,并且CK7可以用作对CCRC反应的预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号